Rizatriptan Benzoate
Product Images NDC 54868-6394

6 FDA label images from Physicians Total Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 54868-6394). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Package Label (54868 6394 1)

Package Label (54868 6394 1)
Packaging label for rizatriptan benzoate 10 mg tablets by Physicians Total Care, Inc., package containing 12 tablets. The label includes the product NDC 54868-6394-01, lot number, expiration date (01/60), and a barcode.*
FDA Label Image

Rizatriptan Benzoate Usp Structural Formula (99c66300 Bd75 4b31 9fab 88c6e4b12688 01)

Rizatriptan Benzoate Usp Structural Formula (99c66300 Bd75 4b31 9fab 88c6e4b12688 01)
Chemical structure of rizatriptan benzoate, displayed as molecular diagrams showing the arrangement of atoms and bonds in the compound.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4 (99c66300 Bd75 4b31 9fab 88c6e4b12688 02)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4 (99c66300 Bd75 4b31 9fab 88c6e4b12688 02)
A line graph depicting the estimated probability of response over time post-dose (in hours) for rizatriptan benzoate tablets at dosages of 5 mg and 10 mg compared to placebo. The x-axis represents hours post-dose (0 to 2), and the y-axis shows the estimated probability of response (0% to 100%). The graph shows higher response probabilities for 10 mg than 5 mg and placebo.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4 (99c66300 Bd75 4b31 9fab 88c6e4b12688 03)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4 (99c66300 Bd75 4b31 9fab 88c6e4b12688 03)
A line graph showing the estimated probability of medication or rescue over 24 hours post-dose. It compares placebo and rizatriptan benzoate tablets at 5 mg and 10 mg dosages, illustrating their effect over time with probability percentages on the vertical axes and hours post-dose on the horizontal axis.*
FDA Label Image

Glenmark Logo (99c66300 Bd75 4b31 9fab 88c6e4b12688 04)

Glenmark Logo (99c66300 Bd75 4b31 9fab 88c6e4b12688 04)
FDA Label Image

Glenmark Logo (99c66300 Bd75 4b31 9fab 88c6e4b12688 05)

Glenmark Logo (99c66300 Bd75 4b31 9fab 88c6e4b12688 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.